Risk minimisation materials: Tresiba® (insulin degludec) poster
Tresiba® is available in two strengths (100 units/mL and 200 units/mL) in the UK. This poster highlights the risk of medication errors associated with mixing up different insulin strengths and the measures that should be taken to minimise this risk.
Source:
Novo Nordisk
SPS commentary:
The manufacturers have also produced related safety information for healthcare professionals and for patients.
A National Patient Safety Alert (NPSA) on the potential for inappropriate dosing of insulin when switching insulin degludec (Tresiba®) products was issued in December 2023.